Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5047-5055

  Zhang, Weiqing ^a   Chuang, Yung Jen ^b,c   Jin, Tianquan ^a   Swanson, Richard ^a   Xiong, Yan ^a   Leung, Lawrence ^b   Olson, Steven T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BASIC FIBROBLAST GROWTH FACTOR; BIGLYCAN; CASPASE 3; EARLY GROWTH RESPONSE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERLECAN; PROTEIN P21; PROTEOGLYCAN; STAT2 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; SYNDECAN 1; SYNDECAN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL SURFACE; COLON POLYPOSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; MICROARRAY ANALYSIS; NORTHERN BLOTTING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UMBILICAL VEIN; UPREGULATION; VALIDATION PROCESS; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANTITHROMBINS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33744911983     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4449     Document Type: Article

References (54)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
2. Gastl G, Hermann T, Steurer M, et al. Angiogenesis as a target for tumor treatment. Oncology 1997;54:177-84.
3. Tandle A, Blazer DG III, Libutti SK. Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2004;2:22-41.
4. Björk I, Olson ST. Antithrombin, a bloody important serpin. In: Church FC, Cunningham DD, Ginsburg D, Hoffman M, Stone SR, Tollefsen DM, editors. Chemistry and biology of serpins. New York: Plenum Press; 1997. p. 17-33.
5. O'Reilly MS, Pine-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8.
6. Larsson H, Sjoblom T, Dixelius J, et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000;60:6723-9.
7. Zhang W, Swanson R, Izaguirre G, Xiong Y, Lau LF, Olson ST. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 2005;106: 1621-8.
8. Kisker O, Onizuka S, Banyard J, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 2001;61:7298-304.
9. Prox D, Becker C, Pirie-Shepherd SH, Celik I, Folkman J, Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 2003;68:47-54.
10. Zhang W, Chuang Y-J, Swanson R, et al. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004;103:1185-91.
11. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-56.
12. Olson ST, Björk I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993;222:525-60.
13. Sherlock G, Hernandez-Boussard T, Kasarskis A, et al. The Stanford Microarray Database. Nucleic Acids Res 2001;29:152-5.
14. Yi M, Sakai T, Fässler R, Ruoslahti E. Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci U S A 2003;100:11435-8.
15. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 2003;72:743-81.
16. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev 2001;1:55-67.
17. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83.
18. Denault JB, Salvesen G. Caspases: keys in the ignition of cell death. Chem Rev 2002;102:4489-99.
19. Aviezer D, Hecht D, Safran M, Eislinger M, David G, Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis and angiogenesis. Cell 1994;79:1005-13.
20. Aviezer D, Iozzo RV, Noonan DM, Yayon A. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol 1997;17:1938-46.
21. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 1998;102:1599-608.
22. Filla MS, Dam P, Rapraeger AC. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J Cell Physiol 1998;174:310-21.
23. Chernousov MA, Carey DJ. N-syndecan (syndecan 3) from neonatal rat brain binds basic fibroblast growth factor. J Biol Chem 1993;268:16810-4.
24. Fahmy RG, Dass CR, Sun L-Q, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003;9:1026-32.
25. Garcia J, Ye Y, Arranz V, Letourneux C, Pezeron G, Porteu F. IEX-1: a new ERK substrate involved in both ERK survival activity and ERK activation. EMBO J 2002;21:5151-63.
26. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE. FGF-20 and DKK1 are transcriptional targets of β-catenin and FGF-20 is implicated in cancer and development EMBO J 2005;24:73-84.
27. Bartoli M, Gu X, Tsai NT, et al. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem 2000;275:33189-92.
28. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 1996;74:589-607.
29. Scovassi AI, Diederieh M. Modulation of poly(ADP-robosylation) in apoptotic cells. Biochem Pharmacol 2004;68:1041-7.
30. Antonsson B, Martinou J-C. The Bcl-2 protein family. Exp Cell Res 2000;256:50-7.
31. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.
32. Boudreau N, Bissell MJ. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 1998;10:640-6.
33. Iozzo RV SanAntonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001;108:349-55.
34. Sanderson RD. Heparan sulfate proteoglycans. Semin Cell Dev Biol 2001;12:89-98.
35. 3 binding to human α5-laminins facilitates FGF-2 and VEGF-induced proliferation of human ECV304 carcinoma cells. Eur J Cell Biol 2003;82:105-17.
36. Spiecker M, Darius H, Liao JK. A functional role of IkB-α in endothelial cell activation. J Immunol 2000;164:3316-22.
37. Bix G, Iozzo RV. Matrix revolutions: "tails" of basement-membrane components with angiostatic functions. Trends Cell Biol 2005;15:52-60.
38. Huang H, Campbell SC, Nelius T, et al. α1-Antitrypsin inhibits angiogenesis and tumor growth. Int J Cancer 2004;112:1042-8.
39. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57.
40. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101:2476-81.
41. Veitonmaki N, Cao R, Wu LH, et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for K1-5-induced antiangiogenesis. Cancer Res 2004;64:3679-86.
42. Doree M, Galas S. The cyclin-dependent protein kinases and the control of cell division. FASEB J 1994;8:1114-21.
43. Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth receptors. Front Biosci 2000;275:24653-60.
44. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9:726-35.
45. Karnitz LM, Abraham RT. Cytokine receptor signaling mechanisms. Curr Opin Immunol 1995;7:320-6.
46. Wei D, Lem X, Zheng L, et al. STAT3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003;22:319-29.
47. Kaufmann K, Bach K, Thiel G. Extracellular signal-regulated protein kinases Erk1/Erk2 stimulate expression and biological activity of the transcriptional regulator EGR-1. Biol Chem 2001;382:1077-81.
48. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ. Expression of early growth response genes in human prostate cancer. Cancer Res 1998;58:2461-8.
49. Abdulkadir SA, Qu Z, Garabedian E, et al. Impaired prostate tumorigenesis in EGR-1-deficient mice. Nat Med 2001;7:101-7.
50. Yabe T, Herbert JT, Takanohashi A, Schwartz JP. Treatment of cerebellar granule cell neurons with neurotrophic factor pigment epithelium-derived factor in vitro enhances expression of other neurotrophic factors as well as cytokines and chemokines. J Neurosci Res 2004;77:642-52.
51. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. Pedf expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003;63:4626-31.
52. Yang S-H, Jeffrey E, Hay RT, Sharrocks AD. Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol Cell 2003;12:63-74.
53. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev 2002;3:207-14.
54. Lu W, Zhou X, Hong B, Liu J, Yue Z. Suppression of invasion in human U87 glioma cells by adenovirus-mediated co-transfer of TIMP2 and PTEN genes. Cancer Lett 2004;214:205-13.